Drugmakers have watched their products become performance-enhancing tools for athletes for years. Steroids, human grown hormone and the now-notorious EPO, among others, came out of Big Pharma's labs for entirely different purposes, but made their way into the competitive medicine chest.

Now, after Lance Armstrong's spectacular fall from grace, more drugmakers are joining up with anti-doping authorities to nip abuse in the bud, The New York Times reports. GlaxoSmithKline ($GSK)--which sponsored the testing lab for the 2012 Olympics--and Roche ($RHHBY) have both shared proprietary information with the World Anti-Doping Agency, including data on drugs still in development. Smaller companies are doing the same.

For GSK, the Olympics lab inspired more work with WADA, including development of new tests for particular compounds. "What the London 2012 involvement led to was a real pride and willingness, and a positive attitude toward this continued engagement," GSK's Pauline Williams told the Times.